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Abstract
Natural antibodies constitute a first-line of defence against pathogens; they may also play other roles in immune
regulation and homeostasis, through their ability to bind host antigens, surface molecules and receptors. Natural
anti-CCR5 antibodies can be decisive in preventing HIV infection in mucosal tissues and offer prompt and effective
protection just at major sites of virus entry. Among natural anti-CCR5 antibodies, IgG and IgA to the ECL1 domain
have been shown to block HIV effectively and durably without causing harm to the host. Their biological proper-
ties and their uncommon generation in subsets of HIV-infected and HIV-exposed individuals (so called ESN) will be
introduced and discussed, with the aim at exploiting their potential in therapy and prevention.
Natural antibodies
Human serum usually contains natural IgG, IgM and
IgA antibodies, generated independently of any exposure
to foreign antigens or vaccines or elicited in the course
of infectious or autoimmune diseases. Most of these nat-
ural antibodies also are polyreactive, i.e. able to bind
various antigens; they are often self-reactive, i.e. capable
of recognizing some host antigens. Natural antibodies
are generated by the B-1 subset of B cells without the
intervention of T cells, therefore belong to the innate
arm of the immune system [1].
B-1 cells are found in peritoneal and pleural cavities
where they provide first-line defence through antibodies
able to bind polysaccharide antigens and repeated motifs
that are typically found in microbial cell walls and
macromolecules [2,3].
Innate defences are important in cutaneous and espe-
cially in mucosal linings, that are the host physical
boundaries with the environment; here, natural, poly-
reactive IgM and IgA antibodies, produced by the “pri-
mordial”, T-independent B cells, control auto-antigens,
exogenous antigens and microbes. Specific, monoreac-
tive antibodies from the adaptive B-cell system (the
large, B-2 subset) are produced later, after the activa-
tion and recruitment of T-cells. In other words, if the
antigen-antibody reaction is compared to a “key-and-
lock” model, natural antibodies found in human
secretions act as “passe-partout” keys to offer a back-
ground protection against most pathogens, food antigens
and microbes, before the antigen-specific response can
develop [4]. B-1 cells features and activities are still
largely unknown, especially in human immunology, and
are currently an active field of investigation. According
with studies of cell transplants performed in transgenic
mice, B-1 population can be divided in two further sub-
set (B-1a and B-1b), which display different phenotypes,
origins and functions. CD5
+ B-1a cells stem from fetal
cells and can self-replicate, while CD5
─ B-1b cells derive
from bone marrow precursors common to B-2 cells, that
constitute the large majority of the B cell population [2];
however, recent experiments have observed the develop-
ment of both B-1 cell subtypes from bone marrow cell
lineages [5,6]. Most B-1 cells display a reduced BCR
diversity and affinity, due to the lack of somatic recombi-
nation and to the poor activity of receptor editing, that
increases with age [6,7]. Most natural antibodies are IgM
[8], but B-1 cells undergoing immunoglobulin class
switch have been recently described [9].
B-1a cells become activated in response to antigens
stimulation [10], and can directly produce antibodies
without the intervention of T-helper cells, while B-1b
cells can take part in adaptive immunity by providing a
specialized type of IgM memory cells [11-13].
Several functions have been proposed for natural
antibodies, including a first–line role in the defense
against infections, a scavenger-like activity to apoptosis
by-products and a turn-off, regulative role in the
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prisingly, pools of intravenous immunoglobulins from
healthy donors were shown to contain antibodies
directed against several cell surface molecules, includ-
ing CD4, CD5, cytokine receptors, adhesion motifs and
CD95 (Fas receptor) [15].
Natural, polyreactive and anti-self antibodies have
been also found in mucosal secretions, such as colos-
trum and saliva [1,4,16]; high-specific S-IgA were
observed in mucosal secretions, where showed a stron-
ger anti-bacterial activity than their serum counterparts,
supporting the primary role of S-IgA in controlling
mucosal infections.
B-1 cells are more prompt than B-2 subpopulation to
switch to IgA production in response to antigen stimula-
tion; their contribution accounts for half of IgA found in
serum or in intestinal lamina propria [17]. Antimicrobial
efficiency of S-IgA was found to be enhanced by their
binding to pFv, a gut-associated molecule, suggesting
that these immunoglobulins took part in controlling gut
infections [4]. How natural antibodies can bind unrelated
epitopes, instead of exhibiting the conventional mono-
reactivity, is still undetermined; some studies suggested a
role for the CDR3 framework region of the heavy immu-
noglobulin chain, a domain where even single mutations
might dramatically alter the specificity and/or the affinity
of the antibody molecule for its target antigen [18,19].
Natural reactive autoantibodies recognizing CCR5 have
been isolated from pools of immunoglobulins from
healthy donors [15]. The role of similar responses, gener-
ated in the absence of autoimmune diseases, is still
debated; antibodies to CCR5 and to other immune recep-
t o r sa n dm e d i a t o r sw e r es u p p o s e dt ob ei n v o l v e di nt h e
maintenance of immune homeostasis. As an example,
anti-CCR5 antibodies could limit the migration of CCR5
+ proinflammatory cells (e.g. macrophages, dendritic
cells, CTLs and Th1 lymphocytes) toward inflammatory
sites releasing CCL5/RANTES, CCL3/MIP-1alpha or
CCL4/MIP-1beta, in order to limit excessive and harmful
effects of inflammation [20]. More importantly, anti-
CCR5 natural antibodies also showed HIV-blocking
properties [15,21,22]. Anti-CCR5 antibodies were even
found in CCR5-lacking subjects, homozygous carriers of
the Delta32 mutation, after repeated exposure to part-
ner’s CCR5+ cells through sexual activity [21]. The find-
ing is not surprising, since allogeneic immunization has
been shown to induce anti-CCR5 antibodies [23].
Different types of antibodies to CCR5 have been
isolated from HIV-infected and from HIV-exposed,
seronegative (ESN) subjects. Most anti-CCR5 antibo-
dies recognized the N-terminus and especially the sec-
o n de x t r a c e l l u l a rl o o p( E C L 2 )o ft h er e c e p t o r ,t h e
immunodominant region involved in chemokine and in
HIV binding [1,15,16,21,24,25]. According to studies
employing anti-CCR5 monoclonal antibodies (mAbs),
some of the immunoglobulins with these two specifici-
ties competed for chemokine binding, blocked HIV
docking or, more significantly, prevented cell fusion
and virus entry [26,27].
A special subset of anti-CCR5 antibodies recognized
the first external loop of CCR5 receptor (ECL1), a
d o m a i nn o ti n v o l v e di nl i g a n db i n d i n go ri nH I Vd o c k -
ing. Anti-CCR5 antibodies to the ECL1 domain
have been detected in serum and mucosal secretions
from exposed, HIV-negative (ESN) people and in some
HIV-positive subjects, both men and women. A study
observed such anti-CCR5 antibodies in thirteen out of
forty-six HIV-positive donors; the presence of anti-
CCR5 antibodies was not significantly associated with
either CD4+ T-cell counts (range: 19-1,047 cells/mL) or
with viral load (range: <50–119,000 copies/mL) [28].
However, findings from broader cohorts, including
subpopulations of HIV progressors and long-term non
progressing (LTNP) individuals, support the hypothesis
that anti-ECL1 IgG and IgA may be involved in HIV
protection or in the infection control [22,29,30].
Anti-CCR5 antibodies in mucosal secretions
Anti-CCR5 antibodies were isolated not only from the
sera of HIV-infected or ESN individuals but also from
all types of mucosal secretions, such as saliva, breast
milk and genital secretions [1,16,29,30].
Anti-CCR5 antibodies were isolated from serum and
mucosal secretions of eight out of 118 ESN individuals,
all sexual partners of HIV-positive patients: interest-
ingly, all males and females carrying CCR5-specific gen-
ital IgA also displayed salivary antibodies, a finding
showing the generation of both systemic and local
responses to HIV exposure. Anti-CCR5 antibodies spe-
cifically recognized synthetic peptides corresponding to
ECL2 and ECL1 domains and blocked HIV infectivity in
PBMC cells [29].
IgG and IgA specific to the ECL2 domain of CCR5
receptor were found in breast milk of HIV-negative and
HIV-positive women (66% and 83%, respectively).
Despite the higher avidity shown by antibody pools
from HIV-positive women, both anti-CCR5 antibodies
inhibited up to 75% infection of macrophages and den-
dritic cells with HIV isolates, showing that natural anti-
bodies provided by breast milk could protect newborns
from HIV transmission [16]. Further results supporting
a possible role of natural anti-CCR5 antibodies also
came from the study of an African cohort of newborns
from HIV-positive mothers. Twenty-five out of thirty-
three children remained uninfected and showed high
levels of specific anti-HIV neutralizing antibodies [31]; a
subset of these children and their mothers also displayed
HIV-blocking antibodies to CCR5 [32].
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polyreactive natural antibodies, mainly IgG and S-IgA
and, to a lesser extent, IgM; in these pools, anti-CCR5
immunoglobulins have been found by different investi-
gators [1,24,29,33]. Natural anti-CCR5 antibodies from
cervicovaginal fluid samples isolated from HIV-negative
women reduced levels of infection in macrophages and
dendritic cells challenged with R5- but not X4- HIV
strains [1]. Genital and salivary IgA to the ECL1 domain
specifically competed with chemokines for CCR5 bind-
ing and downregulated the receptor from PBMC sur-
face; more importantly, only natural antibodies with this
specificity blocked HIV transcytosis across an epithelial
cell layer mimicking the human mucosa. This result was
noteworthy, because other anti-CCR5 antibodies, such
as 2D7, that prevented HIV interaction with CCR5 core-
ceptor by binding to ECL2 domain, was unable to block
virus transcytosis [22,33,34].
A broad clinical study searched for anti-CCR5 antibo-
dies to ECL1 in 497 subjects, including 85 LTNPs, 70
HIV-progressors, 135 HIV-positive patients receiving
highly active antiretroviral therapy (HAART) and 207
HIV-negative donors [30]. Anti-CCR5 antibodies were
isolated in 23% of the LTNP subjects but not in the
other subpopulations studied (P<0.001). Anti-CCR5
antibodies recognized a conformational epitope within
the ECL1 domain and induced a stable and long-lasting
downregulation of CCR5 from the surface of T lympho-
cytes, thereby inhibiting HIV entry. Receptor internaliza-
tion was specifically inhibited by sucrose, but not by
filipin or nystatin, nocodazole or cytochalasin D, thus
supporting a specific role for clathrin-coated pits and
excluding the caveolae compartments [30]. In addition,
CD4
+ lymphocytes from the LTNP subpopulation who
displayed anti-CCR5 antibodies were resistant to in vitro
infection with R5-tropic HIV-1 strains, due to CCR5
downregulation; finally, anti-CCR5 antibodies blocked in
vitro infectivity of HIV primary isolates belonging to
clades A, B and C. The level of ECL1-specific anti-
CCR5 antibodies appeared to be correlated with levels
of HIV exposure, being lower in seronegative ESN sub-
jects and higher in seropositive LTNP individuals (0.1%
vs. 8% of the total antibodies, respectively).
Interestingly, the loss of anti-CCR5 antibodies was
observed in the course of the clinical follow-up and this
event was significantly associated with clinical progres-
sion toward disease in 9 out of 20 LTNP enrolled in the
study; these LTNPs experienced a significant increase in
viremia and required therapy, thus becoming “progres-
sors”. Strikingly, patients who retained anti-CCR5 anti-
bodies did maintain a stable LTNP status without any
treatment. According to the finding, the loss of anti-
CCR5 Abs was associated with progression toward dis-
ease; this observation was strongly supported by the
development of AIDS in some patients despite antiretro-
viral therapy [30].
CCR5 domains and HIV binding: lessons from
anti-CCR5 mAbs
Several studies employing monoclonal antibodies have
defined CCR5 epitopes involved in major receptor func-
tions, such as binding to chemokines, activation, traf-
ficking and HIV docking. Some of these antibodies, such
as MC-1 or PA14, were found suitable to work as thera-
peutic inhibitors of viral entry, due to their ability in
inhibiting gp120 binding or in promoting CCR5 interna-
lization without triggering intracellular signaling; the
humanized version of PA14, PRO140, has been tested in
clinical studies [26,27,35]. A scheme representing CCR5
molecule, its binding domains and the key epitopes
mapped on its structure is illustrated in Figure 1. Simi-
larly to other G-protein coupled receptors (GPCRs) and
membrane-associated proteins, CCR5 is poorly immuno-
genic; its four extracellular domains represent about one
fourth of its whole sequence (90 out of 352 aminoacids);
the two longer domains, the N-terminus and the second
extracellular loop (ECL2), span about 30 aminoacids
each [36]. These latter domains host immunodominant
epitopes recognized by the majority of monoclonal anti-
bodies, such as D2-Y3, Y10-D11 or K171-E172 [36];
both the N-terminus and the ECL2 domain are also
involved in chemokine and HIV binding [26,36,37].
Alanine mapping and point mutation studies have
identified critical aminoacids on the CCR5 molecule,
leading to design epitope maps and theoretical models
representing the extracellular domains of the receptor
and their hypothetical interactions [26,27]. Not surpris-
ingly, few monoclonal antibodies were able to bind
native and denatured CCR5 in Western blot assays, a
finding showing that most CCR5 epitopes are conforma-
tion-sensitive [37]. Key aminoacids included in discon-
tinuous, conformational epitopes may embrace one or
more residues among the first 20 aminoacids in the
N-terminus, other aminoacids in two distinct regions
within the ECL2 domain and single aminoacids belong-
ing to other domains, such as the D95 residue located
in the ECL1 [36]. 2D7, one of the most potent antibo-
dies described in many studies, binds to aminoacids
Q170-K171-E172 and W190 in the ECL2 domain
[26,27,37]. Antibodies targeting the N-terminus domain
of CCR5, as MC-5 or PA9, competed for binding of
soluble gp120-CD4 complex with high affinity, but were
less effective than the ECL2-specific antibodies in pre-
venting cell-cell fusion and virus entry [27,38]. Conver-
sely, antibodies to the ECL2 domain, as 2D7, did not
prevent gp120-CD4 complex binding effectively but
were strong inhibitors of HIV entry; these findings sup-
ported a model of dual interaction between CCR5 and
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between V3 stem on the viral protein and the N-termi-
nus of the coreceptor, occurred before the second one,
which took V3 crown in close contact with the ECL2
domain and triggered HIV envelope-cell membrane
fusion; both interactions with N-terminus and ECL2
domains were required for HIV docking [27,36].
The ECL2 domain hosts both HIV- and chemokine-
specific binding sites; antibodies recognizing this domain
were effective in preventing chemokine binding and/or
signaling [37]. Antibodies recognizing conformational
epitopes spanning different extracellular domains of the
CCR5 molecule displayed different ability in inducing
ligand binding, signaling and receptor trafficking (e.g.
desensitization, phosphorylation, downregulation). For
example, the MC-6 antibody activated CCR5 but was
unable to induce receptor internalization, whereas MC-1
caused CCR5 internalization, via cholesterol-rich raft
domains; MC-4 specifically inhibited CCL5/RANTES-
mediated endocytosis, but did not affect chemokine
signaling [26]. PA9 and PA12, all recognizing CCR5
N-terminus, were ineffective at blocking intracellular
signaling, while PA14 and 2D7 prevented intracellular
calcium mobilization induced by chemokine binding
[27]. The wide spectrum of effects mediated by the
binding of different antibodies supported the existence
of multiple conformations for CCR5 molecules [26].
Most importantly, the modulation of specific events
associated with the coreceptor, such as ligand binding,
signaling and downregulation, opened the way to the
use of monoclonal antibodies as therapeutic tools, cap-
able of preventing HIV spread by steric hindrance and/
or by receptor internalization without affecting physiolo-
gic chemokine signaling. Moreover, antiviral antibodies
could also fight viruses by inducing antibody-dependent
cellular cytotoxicity (ADCC), by virus opsonization and
Figure 1 CCR5 coreceptor. Scheme illustrating the three-dimension structure of CCR5 coreceptor. Extracellular domains show the HIV binding
sites and the immunodominant epitopes mapped by mAbs and by natural anti-CCR5 antibodies. Sites of O-Glycosylation (Ser6), palmitoylation
(Cys321, 323 and 324) and phosphorylation (Ser336, 337, 342 and 349) are also shown. C20-C269 disulphide bond is represented in an open
form.
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[39]. Another interesting feature shown by some mono-
clonal antibodies was the possibility to obtain synergistic
antiviral activity, due to the existence of various non-
overlapping epitopes involved in HIV binding, docking
and entry [40].
The generation of anti–CCR5 antibodies
Anti-CCR5 antibodies have different ways of generation
and different mechanisms of action. Anti-CCR5 antibo-
dies to the chemokine or to the HIV binding site,
i.e. recognizing the N-terminus and/or the ECL2
domain, usually appear in response to experimental
immunization with cells expressing CCR5 or to HIV
infection; these antibodies block HIV entry by binding
competition or steric hindrance [16,36]. Antibodies to
the immunodominant ECL2 domain were also found in
Delta32 homozygous subjects, in response to the sexual
exposure to CCR5+ cells from their sexual partners; in
these cases, CCR5 worked as an alloantigen, similarly to
non-self HLA molecules in HLA-discordant sexual part-
ners [21,41,42].
Finally, anti-CCR5 antibodies recognizing the ECL1
domain of the protein can appear in response to HIV
exposure, or even independently from it. These antibo-
dies do not interfere with HIV binding directly, but
induce co-receptor downregulation, thus blocking virus
infectivity by an indirect way [22,34,43].
Anti-CCR5 antibodies to ECL1 domain are not com-
monly observed in people who are exposed to or
become infected with HIV. In order to explain their
generation, various hypotheses can be formulated. First,
this type of anti-CCR5 antibodies is probably elicited by
low levels of HIV-specific stimulation; this idea is sup-
ported by the fact that these antibodies have been found
in ESN and LTNP people but not in subjects who did
not experienced HIV exposure or in fast progressing
HIV-positive people. The persistence of very low, unde-
tectable levels of HIV replication may provide a contin-
uous antigen boost that does not result in a strong
generalized immune activation; this kind of HIV expo-
sure could be similar to what was observed in the
course of natural latent viral infections (e.g.,h e r p e s -
viruses), in the exposure to food-borne antigens and/or
to oral vaccines, which may establish tolerance and
nevertheless retain their antigenic potential [44,45].
Second, anti-CCR5 Abs can be due to antigenic stimula-
tions other than HIV; this hypothesis finds its root in
the natural history of other viral infections, where
virus-induced alterations of self antigens can give rise to
auto-immunogenic proteins and to the corresponding
auto-antibodies [46]. Host factors itself, as endogenous ret-
roviruses (ERVs) or other latent or concomitant viral infec-
tions, could induce such perturbations in host cells, finally
leading to conformational changes in host receptors and to
the reshaping of self proteins in non-self, antigenic epitopes
[47-50]. In these rare hosts, CCR5 conformation would be
affected by atypical local conditions or by host factors with
the potential to induce autoimmune antibodies, that block
HIV replication by acting on the coreceptor, rather than
on the HIV virus.
Third, some individuals could possess an auto-reactive
pool of B-memory cells, due to a previous priming
caused by endogenous retroviral proteins sharing
homology with HIV env proteins. Once exposed to HIV,
these subjects will promptly generate specific responses
to antigens mimicking viral particles. The two latter
hypotheses found confirmation in the behaviour of
some animal ERVs, such as the Jaagsiekte sheep retro-
virus (JSRV) or the avian leucosis virus (ALV), which
expressed env proteins to prevent infections from exo-
genous retroviruses [51,52].
In ESN and LTNP individuals who were able to con-
trol HIV, host physiological and immunological condi-
tions might have established a positive feedback cycle
that maintained undetectable levels of virus replication
and a suitable antigen presentation on one hand and
long-lasting responses, capable of blocking HIV through
its major coreceptor on the other, therefore providing a
key mechanism for fighting HIV replication [53].
Another remarkable point in the clinical study pre-
viously described was the observation that the viral phe-
notype in LTNP patients carrying anti-CCR5 antibodies
did not change in the presence of such antibodies, thus
confirming that the selective pressure of CCR5 inhibi-
tors did not induce a change of viral phenotype per se,
as already reported in a monkey model [54]. In addition,
anti-CCR5 antibodies did not cause any apparent altera-
tions in the immune function, as demonstrated by the
continued health status of subjects who retained anti-
CCR5 antibodies; both these findings provide an argu-
ment against theoretical concerns about CCR5 targeting
with specific antibodies.
Passive immunization to CCR5
Humanized monoclonal antibodies recognizing CCR5
extracellular domains (the N-terminus and/or the ECL2)
have been developed and competed with gp120 binding
[55]. Passive immunization with humanized monoclonal
antibodies may offer several advantages in respect to
other antiviral drugs. Monoclonal antibodies are highly
target-specific and therefore they minimize side effects
or toxicity; their very long plasma half-lives allow
biweekly or even monthly administrations; antibodies
are proteins administrated intravenously, hence their
pharmacokinetics, metabolism and toxicity differ from
those of HIV-inhibiting drugs, that are low molecular
weight molecules administered per os. Moreover,
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spectra of antiviral and anti-chemotaxis activities. On
the other hand, antibody-based drugs also have disad-
vantages, such as the inconvenience of intravenous
administration, the potential for inducing allergic reac-
tions and the possible development of neutralizing anti-
antibodies [40].
PRO140 and another antibody, HGS004, have been
tested in HIV-infected patients [56,57]. At nanomolar
concentrations in vitro, PRO140 blocked HIV strains
belonging to different clades both in primary macro-
phages and in PBMC [35]. PRO140 inhibited HIV with-
out blocking the CCR5 response to chemokines,
whereas HGS004 prevented both viral infection and
chemokine signaling. Notably, antibodies and small-
molecule antagonists did not share the same mechanism
and site of action; therefore, their activity might be
synergic or contrasting and no cross-resistance was
observed [55]. Resistance to a monoclonal antibody was
only observed in vitro, where mAb-adapted HIV strains
developed several mutations in gp120, becoming resis-
tant to the antibody block [58]. The mechanism for the
development of resistance to 2D7 was unclear, but it
was related to the strong selective pressure exerted on
the hypervariable V3 loop of HIV, that competed with
2D7 antibody for ECL2 binding. Despite CCR5 blocking,
tested HIV strains did not show any R5-to-X4 shift in
coreceptor usage. Results from this study led to formu-
late the hypothesis that antibodies recognizing multido-
main, conformational epitopes, such as PA14/PRO140,
should not induce resistance, due to the nature of their
molecular targets and to their mechanism of action, that
did not affect CCR5-gp120 interaction but post-binding
events [59]. Table 1 summarizes main biochemical and
biological properties of antibodies described in the
review.
Induction of anti-CCR5 immunity
Other experiments, carried out on mice and monkeys,
showed that anti-CCR5 antibodies could be elicited in
Table 1 Antibodies recognizing CCR5 domains and their biologic properties
Table 1. Biological properties of some monoclonal and natural antibodies to CCR5; modified from [36].
Antibody Source Binding
domain
Epitope(s) Biologic properties References
2D7 mAb ECL2 Q170, K171, E172, W190 Inhibition of chemokine binding
Inhibition of cell activation (no Ca
++ flux)
R5-HIV blocking
[27]
PA9 mAb N-term
ECL2
D2, Y3, Q4, S7, P8, N13
Y176, T177
Inhibition of chemokine binding [27]
PA14
PRO140
mAb
hu mAb
N-term
ECL2
D2
R168, Y176
Inhibition of chemokine binding
Inhibition of cell activation (no Ca
++ flux)
R5-HIV blocking
[27]
[35,56]
HGS004
(HGS101)
hu mAb ECL2 Not available Inhibition of chemokine binding without signaling
HIV blocking
[57]
MC-1 mAb ECL2 Not available Inhibition of CCL4/MIP-1beta and CCL5/RANTES
binding
CCR5 dimerization
CCR5 internalization
Inhibition of R5-HIV binding
[26]
MC-4 mAb ECL2 Not available CCL5/RANTES-mediated signaling
Inhibition of CCR5 endocytosis
[26]
MC-6 mAb Multi-
domain
conformational, multi-
domain epitope
including K171, E172
CCL5/RANTES signaling without CCR5
internalization
[26]
RoAb12
RoAb14
RoAb18
mAb ECL2 K171, E172, W190 Inhibition of CCR5-mediated cell fusion
Inhibition of CCL3/MIP-1alpha, CCL4/MIP-1beta,
CCL5/RANTES binding
Inhibition of cell activation (no Ca
++ flux)
Block of R5-HIV strains
[38,40]
Natural anti-
CCR5
Abs
Healthy donors
Delta32
+/+
CCR5- ESNHIV-
positive
ECL2 N-
term
Unknown within R168-K197
sequence
Competition for chemokine binding
Binding to native CCR5 on PBMC
Block of R5-HIV laboratory and primary isolates
[1,15,16,21]
Natur alanti-
CCR5
Abs
ESN
LTNP
ECL1 D95, F96 A95, A96 (gain of
function)
A89, A103 (loss of function)
Inhibition of CCL4/MIP-1beta chemotaxis
Binding to native CCR5 on PBMC
CCR5 downregulation
Block of HIV transcytosis across membranes
Block of R5-HIV isolates from A, B, C, E clades
[22,29,30,33,81]
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required [34,60,61]. Most importantly, anti-CCR5 IgG
and IgA generated by immunization shared HIV-block-
ing properties with human monoclonal immunoglobu-
lins and with natural antibodies found in exposed
individuals [22,34].
Immunization experiments and in vitro studies of eli-
cited antibodies were performed by Chain et al. [62],
who immunized rabbits with chimeric peptides corre-
sponding to a very short fragment of the N-terminal
sequence of CCR5 (M1-S7 or D2-S7) and with a T-spe-
cific peptide from Tetanus toxoid. T-specific CCR5
epitopes were not included in the immunogen to pre-
vent the development of host autoimmune responses.
Immunization generated a strong antibody response;
binding experiments to N-terminal and full-length
CCR5 suggested that CCR5-binding antibodies were a
small percentage of the total antibodies elicited by
immunization; nevertheless, anti-CCR5 specific antibo-
dies blocked HIV infection of macrophages in vitro.
Devito et al. [63] carried out a long-term immunization
with an intranasal DNA prime followed by a peptide
booster immunization. Delivered antigens were peptides
from gp120 V3 loop, from gp41 (MPER peptides con-
taining the ELDKWAS epitope) and from the CCR5-
ECL2 domain (R168–S185). The vaccination schedule
elicited specific IgG and IgA in sera and in mucosal
secretions (intestinal, vaginal and lung) in immunized
mice. More interestingly, long-term IgG and IgA
responses were still observed after 12 months from
boosting both in serum and in mucosal secretions and
still displayed HIV–blocking properties. According to
this study, an intranasal DNA prime followed by one
peptide/L3 adjuvant booster immunization, but not vice
versa, induced long-lasting HIV-blocking antibodies and
B memory cells to poorly immunogenic, conformational
epitopes. Barassi et al. [34] generated chimeric immuno-
gens containing a CCR5 peptide from the ECL1 domain
(Y89–W102) in the context of the capsid protein of
flock house virus, a conformation-constrained expres-
sion system [64]. Administered to mice by systemic or
mucosal route, the immunogens elicited anti-CCR5 IgG
and IgA both in sera and in vaginal fluids. Similarly to
HIV-exposed seronegative individuals, mice producing
anti-CCR5 autoantibodies expressed significantly
reduced levels of CCR5 on the surfaces of CD4
+ cells
from peripheral blood and vaginal washes. In vitro stu-
dies showed that murine IgG and IgA (i) specifically
bound human and mouse CD4
+ lymphocytes and the
CCR5-transfected U87 cell line; (ii) downregulated
CCR5 expression of CD4
+ cells from both humans and
untreated mice; (iii) inhibited CCL4/MIP-1b chemotaxis
of CD4
+ CCR5
+ lymphocytes and (iv) blocked in vitro
infectivity of R5-HIV strains belonging to clade
B. Finally, Pastori et al. [65] performed a peptide-scan-
ning assay on a panel of synthetic peptides spanning the
CCR5-ECL1 region; the resulting peptides were assayed
with a pool of natural anti-CCR5 antibodies and used to
immunize mice and chickens. Further structural charac-
terization of the peptides was provided by NMR spec-
troscopy and by molecular dynamics simulations.
Aminoacid substitutions in positions 95 and 96 (ECL1,
A95–A96) increased antibody–peptide binding com-
pared to the wild-type peptide (ECL1, D95–F96). The
A95–A96 peptide was shown to induce, in both mice
and chickens, antibodies displaying biological activity at
very low concentrations. Strikingly, chicken antibodies
to the modified peptide A95-A96 specifically recognized
human CCR5 molecules, downregulated receptors from
lymphocytes, inhibited CCR5-dependent chemotaxis and
prevented infection by several R5 primary isolates
belonging to Clades A, B, C and E, displaying IC50
values lower than 3 ng/ml. NMR spectroscopy and
molecular dynamics simulations confirmed the high
flexibility of the isolated epitopes and suggested that
A95–A96 substitutions conferred a slightly higher
tendency to generate helical conformations combined
with a lower steric hindrance of the side chains in the
peptides. The different structural behavior of the muta-
genized loop might account for a better molecular struc-
tural organization, allowing the induction of the fittest
antibodies. Optimized antibodies recognized and bound
native CCR5 with higher affinity and displayed enhanced
biological activity.
Other in vivo studies coupled immunization experi-
ments with in vivo challenges of vaccinated animals to
evaluate whether a break in B-tolerance was achieved
and what was the extent of immune protection con-
ferred by tested immunogens. Chackerian et al.[ 6 0 ]
used the N-terminal domain of pigtailed macaque CCR5
fused to streptavidin. Once conjugated at high densities
to the capsid protein L1 within bovine papilloma
virus-like particles, this immunogen induced high-titer
anti-CCR5 IgG that blocked infection by R5-tropic
simian-human immunodeficiency virus (SHIV) in vitro.
FACS analysis of spleen cells, thymus cells and PBMC
did not detect any decline in the number of CCR5-
expressing cells (T lymphocytes and macrophages) in
immunized animals vs controls. In SHIV-challenged
macaques, viral loads and time to control of viremia
were significantly decreased in respect to controls, indi-
cating that CCR5 auto-antibodies could have contribu-
ted to the control of viral replication. Bogers et al. [66]
assayed a vaccine consisting of three extracellular
peptides of CCR5, an N-terminal HIV gp120 fragment
generated in transgenic plants and the recombinant
simian immunodeficiency virus p27 antigen. They were
linked to the microbial heat-shock protein HSP70, used
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mucosal and systemic routes. Vaginal challenge with
SHIV infected all macaques, with a significant variation
in viral loads between immunized and control animals;
the virus was cleared in five out of nine immunized
animals. Misumi et al. [67] adopted synthetic cyclic
peptides from the ECL2 (R168-T177) to induce anti-
CCR5 antibodies in cynomolgus macaques. The immu-
nization with a conjugated multiple-antigen peptide
(cyclic closed chain dodecapeptide, cDDR5-MAP)
induced long-lasting anti-cDDR5 antibodies reacting
with both human and macaque CCR5 molecules,
which suppressed in vitro infections by an R5-HIV-1
laboratory isolate, by R5-HIV-1 primary isolates
belonging to clade A and C and by a pathogenic SHIV
isolate. After SHIV challenge, the vaccinated cynomol-
gus macaques showed an attenuated acute infection
and a lower viral load than the unvaccinated control
animals.
According to in vitro and in vivo findings, immuniza-
tion did elicit antibodies endowed with HIV-blocking
properties, effectively breaking B-tolerance. Despite the
fact that none of the immunogens assayed in vivo was
able to confer full protection from virus challenge, the
infection of vaccinated subjects was milder than in the
controls and virus control was achieved in most
subjects. Finally, in vitro studies also showed that con-
formational changes in the CCR5 protein, together with
host factors, had the potential to modulate protein
immunogenicity in vivo and might also play a role in
the natural resistance to HIV infection.
Conclusions
Natural antibodies offer a prompt and effective pro-
tection to most microbial infections and are likely to
p l a yap r o t e c t i v er o l ei nH I Vi n f e c t i o na sw e l l .C C R 5
is a key player in HIV entry and many medical
approaches have been focused on it to prevent HIV
infection and/or spread. The clinical use of small
CCR5 inhibitors has proven the feasibility and the effi-
cacy of CCR5 targeting, but it has also raised concerns
about the safety of this approach: drug-resistant R5-
HIV strains have been isolated in cell cultures and in
patients receiving maraviroc and other CCR5 inhibi-
tors [68-70]. The use of humanized monoclonal anti-
bodies has proven effective and safe in HIV-infected
patients, suggesting that passive immunization may
offer therapeutic advantages [56,57]. The use of engi-
neered chemokines induced receptor downregulation,
removing CCR5 from availability for HIV binding;
despite its effectiveness, this approach might be asso-
ciated in vivo with adverse inflammatory events [71].
An HIV vaccine remains the most expected goal to be
accomplished in HIV research, showing its value both
in therapeutic intervention and in prevention [72].
Vaccination may offer long-lasting protection with few
administrations, in a way acceptable in many geogra-
phical and social contexts, where other forms of pre-
vention for sexually transmitted diseases could be
impractical or rejected [73].
Anti-CCR5 vaccination is an innovative anti-HIV
strategy, which could provide effective protection or safe
containment to virus spread. Most importantly, anti-
CCR5 antibodies raised in animal models or naturally
occurring upon HIV exposure showed blocking activity
to different virus clades, a result that was hardly
achieved by conventional HIV-based immunogens
[30,34,60]. Indeed, the feasibility of anti-CCR5 vaccina-
tion has been already demonstrated by two groups of
naturally CCR5-deficient people. Individuals deprived of
CCR5 receptor by genetic deletion [74-76] and those
carrying naturally occurring anti-CCR5 antibodies
downregulating the receptor in vivo [22,29,30] were
found to be healthy and largely resistant to HIV-infec-
tion. Importantly, natural anti-CCR5 antibodies to the
ECL1 domain have been uniquely observed in the sera
and in mucosal fluids of individuals who remained unin-
fected despite repeated and unprotected sexual exposure
to HIV and in HIV-infected individuals with long-term,
asymptomatic infection. The finding that both ESN and
LTNP subpopulations exerted a high and durable con-
trol on the virus confirmed the hypothesis that natural
anti-CCR5 antibodies could be associated with protec-
tion. This concept was further strengthened by the good
health and immune status shown by the LTNP cohort,
confirming that long-lasting CCR5 downregulation was
not harmful; conversely, cohort follow-up showed that
the loss of anti-CCR5 responses experienced by some
patients was associated with a decline in virus control
[30]. These findings are noteworthy because genetic
CCR5 deletion has been associated with an increased
susceptibility to some viral and bacterial pathogens [77];
moreover, anti-self immunity was one of the mechan-
isms evoked to explain the generation of natural
anti-CCR5 antibodies [53] and a possible adverse event
associated with anti-CCR5 vaccination [55]. Conversely,
CCR5 targeting could offer therapeutic advantages in
some autoimmune diseases, as rheumatoid arthritis [78],
or in transplantation therapy, all situations where
chemokine signaling and cell recruitment might sustain
tissue damage [79]. Another key finding from the fol-
low-up of the LTNP cohort was the lack of an R5-to-X4
tropism shift, a fact supporting the safety of antibody-
mediated coreceptor targeting [30]; this is a key point to
be considered, due to the concerns raised by the thera-
peutic use of small-molecule CCR5 inhibitors, which are
prone to in vitro and in vivo drug resistance and might
favor the selection of dual-tropic or X4-tropic virus
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performed in animal models have shown that anti-CCR5
antibodies can be obtained in vivo,p r o v i d e dt h a ts u i t a -
ble vector systems are used, either to break B-tolerance
to the self-CCR5 antigen and to constrain the ECL1
peptide (i.e. the target domain of these natural anti-
CCR5 antibodies) in a conformation similar to the natu-
rally occurring, immunogenic one [34,65]. Moreover,
anti-CCR5 antibodies elicited by the mucosal route are
long-lasting and can be promptly re-boosted upon
immunization, either in sera or, most importantly, in
mucosal fluids, showing the feasibility of local immunity
at major portals of HIV entry [34].
This latter issue can sound paradoxical, because nat-
ural responses generated by B-1 cells should be inde-
pendent from T-helper lymphocytes [2,7,10] and
therefore could not give rise to memory cells, although
some “memory” B-1 cells have been described [12,13].
However, the use of peculiar vectors and adjuvants in
immunization experiments aimed at reproducing
anti-CCR5 antibodies did induce a break in immune tol-
erance, and therefore could have achieved a forced,
“non-natural” response to a self antigen; on the other
hand, even the mechanisms leading to generate some
types of anti-CCR5 antibodies in HIV-exposed people
are still largely undefined [43,53].
Taken together, all of the findings reviewed here
support the significance of interventions focused on
CCR5 in its role as principal HIV coreceptor. Among
all strategies now available or under development,
naturally occurring anti-CCR5 antibodies show the
therapeutic potential to provide durable, effective and
safe systemic and, especially, local immunity to HIV.
As shown by follow-up studies and immunization
experiments, antibody-mediated CCR5 targeting was
not only feasible but it was also well tolerated.
Together with other immune-modulating strategies,
this unconventional approach could open unprece-
dented avenues of treatment not only for HIV/AIDS
but also for other disorders where harmful pro-inflam-
matory responses can develop.
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